Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00426140 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00426140 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT00426140, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The main purpose of this study is to characterize the distribution, metabolism, and elimination (ADME) of Patupilone after a single intravenous administration in patients with advanced solid tumor malignancies
Interventions
- DRUG Patupilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00426140
The ClinicalTrials.gov registry entry for NCT00426140 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Patupilone is the first listed.
NCT00426140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00426140 about?
NCT00426140 is a clinical study titled "Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.". The main purpose of this study is to characterize the distribution, metabolism, and elimination (ADME) of Patupilone after a single intravenous administration in patients with advanced solid tumor malignancies
What is the current status of trial NCT00426140?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2006-08.
What interventions are being tested in trial NCT00426140?
The interventions under investigation include: Patupilone (DRUG).
Who is sponsoring clinical trial NCT00426140?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.